Prospective study of oral adverse events by anti-cancer therapy with immune checkpoint inhibitors

Prospective study of oral adverse events by anti-cancer therapy with immune checkpoint inhibitors - Study of oral adverse events by using immune checkpoint inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041688

Enrollment

100

Registered

2020-11-01

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral mucositis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who suffer oral adverse events during cancer treatments with immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: The patients who are unable to get informed consent

Design outcomes

Primary

Measure	Time frame
Grade of oral oral mucositis	—

Secondary

Measure	Time frame
Examination of dental condition	—

Countries

Japan

Contacts

Public ContactTakeyoshi Koseki

Tohoku University Graduate School of Dentistry Preventive Dentistry

tkoseki@dent.tohoku.ac.jp0227178327

Outcome results